Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells.
Ramona RotoloValeria LeuciChiara DoniniFederica GalvagnoAnnamaria MassaMaria Chiara De SantisSerena PeironeGiovanni MedicoMartina SanlorenzoIgor VujicLoretta GammaitoniMarco BasiricòLuisella RighiChiara RigantiIris Chiara SalaroglioFrancesca NapoliFabrizio TabbòAnnapaola MarinielloElisa VignaChiara ModicaLorenzo D'AmbrosioGiovanni GrignaniRiccardo TaulliEmilio HirschMatteo CeredaMassimo AgliettaGiorgio Vittorio ScagliottiSilvia NovelloPaolo BironzoDario SangioloPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
We report first evidence of a novel lymphocyte-independent activity of anti-PD-1 antibodies in NSCLC, capable of inhibiting chemo-surviving NSCLC cells and exploitable to contrast disease relapses following chemotherapy.
Keyphrases
- small cell lung cancer
- induced apoptosis
- advanced non small cell lung cancer
- peripheral blood
- locally advanced
- cell cycle arrest
- signaling pathway
- magnetic resonance
- photodynamic therapy
- brain metastases
- squamous cell carcinoma
- cancer therapy
- oxidative stress
- rectal cancer
- cell death
- magnetic resonance imaging
- drug delivery
- cell proliferation